



04 June 2025

Cambridge Cognition Holdings plc
("Cambridge Cognition", the "Company" or the "Group")
Posting of Annual Report & Notice of AGM

Cambridge Cognition (AIM: COG), the brain health software group specialising in digital products to advance clinical research and patient treatment, confirms that the Annual Report and Accounts for the year ended 31 December 2024 ("2024 Annual Report and Accounts") and the Notice of the Annual General Meeting ("AGM") have been published on the Company's website today. Hard copies have been posted to those shareholders who requested them.

The AGM is to be held at 9:00 am on 27 June 2025 at the registered office of the Company, Tunbridge Court, Tunbridge Lane, Bottisham, Cambridge, CB25 9TU.

A copy of the 2024 Annual Report and Accounts and other documents are available on the Company's website:
www.cambridgecognition.com

Enquiries:

Cambridge Cognition Holdings plc Rob Baker, Joint Managing Director and Chief Operating Officer	Tel: 012 2381 0700 press@camcog.com
Panmure Liberum Limited (NOMAD and Joint Broker) Freddy Crossley / Will Goode / Mark Rogers Rupert Dearden	Tel: 020 7886 2968 (Corporate Finance) (Corporate Broking)
Dowgate Capital Limited (Joint Broker) David Poutney / Amber Philipps	Tel: 020 3903 7715
Hudson Sandler (Financial PR and IR) Dan de Belder / Hattie Dreyfus / Jackson Redley	Tel: 020 7796 4133 cog@hudsonsandler.com

Notes to Editors

About Cambridge Cognition

Cambridge Cognition is a brain health software group specialising in digital health products that advance brain health research and treatment.

Built on rich, curated data and deep technical expertise we are building a strong global brand with scalable technology that will support the rising world demand for diagnosing and treating brain health. The Company creates shareholder value through organic sales growth, strategic partnerships, joint ventures, and spinouts. The Company has identified four market sectors:

- **Clinical Studies** for new pharmaceuticals;
- **Academic Research** for scientists to understand CNS disorders;
- **Healthcare** to provide physicians with cognitive assessments to allow them to diagnose and treat patients; and,
- **Consumer Health & Wellness** to provide individuals access to accurate, reliable, and meaningful data to assess their cognitive health.

For further information, visit: www.cambridgecognition.com

END

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@lse.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NOAPKNBDOBKDDAK